trending Market Intelligence /marketintelligence/en/news-insights/trending/BSRYsOYXecYKC8nwSSIfhg2 content esgSubNav
In This List

IntelGenx's resubmitted application for migraine drug accepted by US FDA

Blog

Insight Weekly: Bank boards lag on gender parity; future of office in doubt; US LNG exports leap

Blog

Insight Weekly: Job growth faces hurdles; shale firms sit on cash pile; Africa's lithium future

Blog

Insight Weekly: Loan growth picks up; US-China PE deals fall; France faces winter energy crunch

Blog

Perspectives from China: Chinese M&A in 2022


IntelGenx's resubmitted application for migraine drug accepted by US FDA

IntelGenx Technologies Corp. said the U.S. Food and Drug Administration has accepted its resubmitted new drug application for Rizaport VersaFilm, an oral soluble film for acute migraine.

The Montreal-based pharmaceutical company resubmitted the application for the drug in September after it was rejected a second time by the regulator in April.

Earlier rejections by the FDA were based on the regulator's concerns regarding chemistry, manufacturing and controls. The agency also requested additional information regarding the treatment, a proprietary oral thin film formulation of rizatriptan benzoate — the active drug in Merck & Co. Inc.'s Maxalt.

IntelGenx develops oral films — treatments that dissolve in the mouth, delivering certain medicines — using its VersaFilm technology platform.